Journal of Volgograd State Medical UniversityJournal of Volgograd State Medical University1994-94801994-9499Volgograd State Medical University11958810.19163/1994-9480-2021-1(77)-12-16Research ArticleTARGETED DRUG DELIVERY SYSTEMS IN BREAST CANCER CHEMOTHERAPYAl-HumairiA. Hahmed.h.mneahil@gmail.comOstrovskyO. V-ZykovaE. V-SperanskyD. L-FSBEI HE «Volgograd State Medical University» of the Ministry of Healthcare of the Russian FederationSBIH «Volgograd regional clinical oncology center»15012021181121619122022Copyright © 2021, Al-Humairi A.H., Ostrovsky O.V., Zykova E.V., Speransky D.L.2021The article presents a review, systematizing the state and directions of development in the fabrication of targeted drug delivery systems in relation to the treatment of breast cancer. Drug delivery systems constructed on the basis of natural and artificial liposomes, nanoparticles of various nature, polymers, and dendrimer structures are consistently considered. For each class of platforms, information is provided on the features of the structure and functional properties of carriers, on successful examples of their use for the treatment of breast cancer at various stages of preclinical and clinical trials. The most probable directions to achieve a progress in the development of new systems for targeted delivery of antitumor drugs are shown.drug delivery systemstargeted therapynanomedicineliposomesnanoparticlesdendrimersbreast cancerсистемы доставки лекарствадресная терапиянаномедициналипосомынаночастицыдендримерырак молочной железы[Abasi E., Fekri Aval S., Akbarzadeh A., et al. Dendrimers: Synthesis, applications, and properties. Nanoscale Res. Lett, 2014, vol. 9, e247. DOI: 10.1186/1556-276X-9-247.][Alswieleh A.M. Modification of mesoporous silica surface by immobilization of functional groups for controlled drug release. J. Chem, 2020, vol. 2020, e9176257. DOI: 10.1155/2020/9176257.][Arnedos M., Vicier C., Loi S., Lefebvre C. Precision medicine for metastatic breast cancer limitations and solutions. Nat. Rev. Clin. Oncol, 2015, vol. 12, pp. 693-704.][Aruna U., Rajalakshmi R., Vinesha I.M.Y.V., et al. Role of chitosan nanoparticles in cancer therapy. Int. J. Innov. Pharm. Res, 2013, vol. 4 (3), pp. 318-324.][Barile L., Vassalli G. Exosomes: therapy delivery tools and biomarkers of diseases. Pharmacol. Ther, 2017, vol. 174, pp. 63-78. DOI: 10.1016/j.pharmthera.2017.02.020.][Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin, 2018, vol. 68, pp. 394-424.][Chen C., Hou L., Zhang H., Zhu H. Single-walled carbon nanotubes mediated targeted tamoxiten delivery system using aspargine-glycine-arginine peptide. J. Drug Target, 2013, vol. 21 (9), pp. 209-821.][Cho H.J., Yoon I.S., Yoon H.Y., et al. Polyethylene glycolconjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials, 2012, vol. 33, pp. 1190-1200.][DeSantis, C.E., et al. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA: a cancer journal for clinicians, 2016, vol. 66 (4), pp. 290-308.][Feng T., Zhao Y. Clinical anticancer drugs for cancer treatment, in nanomaterial-based drug delivery carriers for cancer therapy, 2017, Springer, pp. 7-13. DOI: 10.1007/978-981-10-3299-8_2.][Hassanpour A., Irandust M., Soleimani E., Zhaleh H. Increasing the anticancer activity of azidothymidine toward the breast cancer via rational design of magnetic drug carrier based on molecular imprinting technology. Mater. Sci. Eng., 2019, e109771. DOI: 10.1016/j.msec.2019.109771.][Hsu H.J., Bugno J., Lee S.R., Hong S., Dendrimer-based nanocarriers: A versatile platform for drug delivery. WIREs. Nanomed. Nanobiotechnol, 2017, vol. 9, e1409.][Huang D., Wu D. Biodegradable dendrimers for drug delivery. Mater. Sci. Eng., 2018, vol. 90. DOI: 10.1016/j.msec.2018.03.002.][Huang L., Liu J., Gao F., et al. Dual-responsive, hyaluronic acid targeted drug delivery system based on hollow mesoporous silica nanoparticles for cancer therapy. J. Mater. Chem. B, 2018, vol. 6 (28), pp. 1-3. DOI: 10.1039/C8TB00989A.][Huang P., Wang D., Su Y., et al. Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug-drug conjugate for cancer therapy. J. Amer. Chem. Soc, 2014, vol. 136(33), pp. 1174811756. DOI: 10.1021/ja505212y.][Jiang Y.-Y., Tang G., Zhang L.-H., et al. PEGylated PAMAM dendrimers as a potential drug delivery carrier: In vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex. J. Drug Target, 2010, vol. 18, pp. 389-403. DOI: 10.3109/10611860903494203.][Kesharwani P., Lyer A.K. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discov. Today, 2015, vol. 20, pp. 536-547.][Li W.-O., Wang Z., Hao S., et al. Mitochondria-targeting polydopamine nanoparticles to deliver Doxorubicin for overcoming drug resistance. ACS Appl. Mater. Interfaces, 2017, vol. 9 (20), pp. 16793-16802. DOI: 10.1021/acsami.7b01540.][Lian B., Wei H., Pan R. Galactose modified liposomes for effective co-delivery of doxorubicin and combretastatin A4. Int. J. Nanomed, 2021, vol. 16, pp. 457-467. DOI: 10.2147/JN.S283793.][Lloyd K.C., Meehan T., Beaudet A. Precision medicine: Look to the mice. Science, 2015, Iss. 349, e390.][Lu R.-M., Chen M.-S., Chang D.-K., et al. Targeted drug delivery systems mediated by a novel peptide in breast cancer therapy and imaging. PLoS ONE, 2013, vol. 8 (6), e66128. DOI: 10.1371/journal.pone.0066128.][Lu S., Neoh K.G., Huang G., et al. Polyacrylamide hybrid nanogels for cancer chemotherapy via co-delivery of gold nanoparticles and MTX. J. Colloid Interface Sci, 2013, vol. 412, pp. 46-55.][Madamsetty V.S., Mukherjee A., Mukherjee S. Recent trends of the bio-inspired nanoparticles in cancer theranostics. Front Pharmacol, 2019, vol. 10, e1264. DOI: 10.3389/fphar.2019.01264.][Narayan R., Nayak U.Y., Raichur A.M., Garg S. Mesoporous silica nanoparticles: a comprehensive review on synthesis and recent advances. Pharmaceutics, 2018, vol. 10, p. 118. DOI: 10.3390/pharmaceutics10030118.][O'Shaughnessy J.A., Kaufmann M., Siedentopf F., et al. Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. The Oncologist, 2012, vol. 17, pp. 476-484.][Pedrosa P., Corvo M.L., Ferreira-Silva M., et al. Targeting cancer resistance via multifunctional gold nanoparticles. Int. J. Mol. Sci, 2019, vol. 20 (21), e5510. DOI: 10.3390/ijms20215510.][Pershina A.G., Brikunova O.Ya., Demin A.M., et al. Variation in tumor pH affects pH-triggered delivery of peptide-modified magnetic nanoparticles. Nanomedicine, 2021, vol. 32, e102317. DOI: 10.1016/j.nano.2020.102317][Pravin P.D., Aashutosh S.U. Chitosan nanoparticles: an e merging weapon against the cancer. MOJ Cell Sci. Rep, 2016, vol. 3 (1), P. 39-40. DOI: 10.15406/mojcsr.2016.03.00049.][Ren L., Zhang Y., Cui C., et al. Functionalized graphene oxide for anti-VEGF siRNA delivery: preparation, characterization and evaluation in vitro and in vivo. RSC Adv, 2017, vol. 7, pp. 20553-20566.][Seeta Rama R.G., Benton L., Pavitra E., et al. Multifunctional nanoparticles: recent progress in cancer therapeutics. Chem. Commun. (Camb), 2015. vol. 51 (68), pp. 13248-13259.][Sharma A., Gautam S.P., Gupta A.K. Surface modified dendrimers: synthesis and characterization for cancer targeted drug delivery. Bioorg. Med. Chem, 2011, vol. 19 (11), pp. 3341-3346. DOI: 10.1016/j.bmc.2011.04.046. Epub 2011 Apr 28. PMID: 21570304.][Shenoy D.B., Amiji M.M. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int. J. Pharm, 2005, vol. 293 (1 -2), pp. 261-270. DOI: 10.1016/j.ijpharm.2004.12.010.][Slingerland M., Guchelaar H.-J., Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discovery Today, 2012, vol. 17, pp. 160-166.][Song H., Su C., Cui W., et al. Folic acid-chitosan conjugated nanoparticles for improving tumor-targeted drug delivery. Biomed. Res. Int, 2013, vol. 2013, e723158.][Soni P., Kaur J., Tikoo K. Dual drug-loaded paclitaxel-thymoquinone nanoparticles for effective breast cancer therapy. J. Nanoparticle Res, 2015, vol. 17 (1), e18.][Sparreboom A., Scripture C., Trieu V.N., et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound Paclitaxel (ABI-007) and Paclitaxel formulated in cremophor (Taxol). Clin. Cancer Res, 2005, vol. 11, pp. 4136-4143.][Svenson S. The dendrimer paradox - high medical expectations but poor clinical translation. Chem. Soc. Rev, 2015, vol. 44, pp. 4131-4144.][Ventola C.L. Progress in nanomedicine: approved and investigational nanodrugs. PT, 2017, vol. 42 (12), pp. 742-755.][Wang L., Shi J., Jia X. pH-Responsive drug delivery of functionalized single-walled carbon nanotubes for potential application in cancer chemo-photothermal therapy. Pharmac. Res, 2013, vol. 30 (11), pp. 2757-2771.][Wilhelm S., Tavares A.J., Dai O., et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater, 2016, vol. 1, e16014. DOI: 10.1038/natrevmats.2016.14.][Xiao J., Duan X., Yin O., et al. Nanodiamonds-mediated doxorubicin nuclear delivery to inhibit lung metastasis of brest cancer. Biomaterials, 2013, vol. 34 (37). e96489654.][Yan S., Zhang X., Sun Y. et al. In situ preparation of magnetic Fe3O4 nanoparticles inside nanoporous poly(l-glutamic acid)/chitosan microcapsules for drug delivery. Colloids Surf. B.: Biointerfaces, 2014, vol. 113, pp. 302-311.][Zeng X., Liu G., Tao W., et al. A drug-self-gated mesoporous antitumor nanoplatform based on pH-sensitive dynamic covalent bond. Adv. Funct. Mater, 2017, vol. 27, e1605985. DOI: 10.1002/adfm.201605985.][Zhu O., Heon M., Zhao Z., et al. Microfluidic engineering of exosomes: editing cellular messages for precision therapeutics. Lab Chip, 2018, vol. 18 (12), pp. 1690-1703. DOI:10.1039/c8lc00246k.]